P.O. Box 650820 Sterling, VA 20165-0820 e-mail: forensics@cts-interlab.com Telephone: +1-571-434-1925

Website: www.cts-forensics.com

Manufacturer's Information Test No. 21-5801: DNA-Mixture

Each sample pack consisted of two known bloodstains on clean, white muslin fabric (Items 1 & 2), and two questioned stains; one on clean pink fabric (Item 3) and one on clean, off-white fabric (Item 4). Participants were requested to analyze these items using their existing protocols.

SAMPLE PREPARATION: The stains in Items 1, 2, and 4 were prepared using human whole blood which was either drawn into citric acid preservative bags or EDTA tubes. The stain in Item 3 was a mixture prepared from human whole blood and semen. The semen sample was first thawed and mixed 1:1 with TAE buffer, then mixed 1:1 with the blood. Item 1 (50 μ I) was created using blood from a female donor. Items 2 (50 μ I) and 4 (50 μ I) were created using blood from the same male donor. Item 3 (50 μ I) was created using a 1:1 mixture of blood from the female donor found in Item 1 and semen from a male donor whose known standard was not provided. Stains from different sources were prepared at separate times and were packaged once they were thoroughly dried. Completed sample sets were stored at -20°C until shipment on January 4, 2021 following receipt of predistribution results.

SAMPLE SET ASSEMBLY: For each sample set, all four Items (1-4) were packed into separate envelopes and then placed together in a pre-labeled sample pack envelope. The sealed sample pack envelopes were then packaged in pre-labeled heat seal envelopes and sealed. This process was repeated until all of the sample sets were prepared.

VERIFICATION: All predistribution laboratories confirmed the manufacturer's expected associations. Consistent allelic results were reported for all STR and YSTR loci.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.

Manufacturer's Information, continued Test No. 21-5801: DNA-Mixture

| Amelogenin and STR Results | | | | | | | | | | | |
|----------------------------|---|---------|----------|-----------|------------|---------|--|--|--|--|--|
| | Results compiled from predistribution laboratories and a consensus of at least 10 participants. | | | | | | | | | | |
| Item | D1S1656 | D2S1338 | D2S441 | D3S1358 | D5S818 | D6S1043 | | | | | |
| | D7S820 | D8S1179 | D10S1248 | D12S391 | D13S317 | D16S539 | | | | | |
| _ | D18S51 | D19S433 | D21S11 | D22S1045 | Amelogenin | CSF1PO | | | | | |
| | FGA | Penta D | Penta E | SE33 | TH01 | TPOX | | | | | |
| | vWA | DYS391 | DYS570 | DYS576 | Y Indel | | | | | | |
| 1 | 15,16 | 21,25 | 11,11 | 16,16 | 9,11 | * | | | | | |
| | 11,11 | 14,15 | 13,16 | 17,20 | 12,12 | 10,11 | | | | | |
| _ | 14,20 | 13,14 | 29,30 | 16,18 | X,X | 10,12 | | | | | |
| | 16.1,23 | 10,11 | 8,13 | 28.2,28.2 | 8,9.3 | 8,11 | | | | | |
| | 14,17 | NM | NM | NM | NM | | | | | | |
| 2 | 15.3,16 | 25,26 | 10,15 | 15,15 | 11,11 | * | | | | | |
| | 9,11 | 10,12 | 13,14 | 15,17 | 10,11 | 10,12 | | | | | |
| | 17,22 | 14,15 | 29,29 | 15,17 | X,Y | 10,11 | | | | | |
| | 18,21 | 10,15 | 10,16 | 15,27.2 | 6,8 | 9,11 | | | | | |
| | 16,17 | 10 | 18 | 17 | 2 | | | | | | |
| 3-Blood | 15,16 | 21,25 | 11,11 | 16,16 | 9,11 | * | | | | | |
| | 11,11 | 14,15 | 13,16 | 17,20 | 12,12 | 10,11 | | | | | |
| | 14,20 | 13,14 | 29,30 | 16,18 | X,X | 10,12 | | | | | |
| | 16.1,23 | 10,11 | 8,13 | 28.2,28.2 | 8,9.3 | 8,11 | | | | | |
| | 14,17 | NM | NM | NM | NM | | | | | | |
| 3-Semen | 15,17.3 | 20,23 | 10,11.3 | 15,15 | 9,11 | * | | | | | |
| | 8,9 | 12,14 | 15,16 | 17,18 | 12,13 | 12,13 | | | | | |
| | 17,17 | 13,14 | 29,29 | 11,15 | X,Y | 10,12 | | | | | |
| | 20,24 | 9,13 | 10,11 | 18,25.2 | 6,8 | 8,12 | | | | | |
| | 14,19 | 11 | * | * | 2 | | | | | | |
| 4 | 15.3,16 | 25,26 | 10,15 | 15,15 | 11,11 | * | | | | | |
| | 9,11 | 10,12 | 13,14 | 15,17 | 10,11 | 10,12 | | | | | |
| | 17,22 | 14,15 | 29,29 | 15,17 | X,Y | 10,11 | | | | | |
| | 18,21 | 10,15 | 10,16 | 15,27.2 | 6,8 | 9,11 | | | | | |
| | 16,17 | 10 | 18 | 17 | 2 | | | | | | |

| YSTR Results | | | | | | | | | | | | | |
|---|----------|--------|---------------|----------|-----------|--------|--------|--------|---------|--|--|--|--|
| Results compiled from predistribution laboratories and a consensus of at least 10 participants. | | | | | | | | | | | | | |
| ltem | DYF387S1 | DYS19 | DYS385 | DYS389-I | DYS389-II | DYS390 | DYS391 | DYS392 | DYS393 | | | | |
| | DYS437 | DYS438 | DYS439 | DYS448 | DYS449 | DYS456 | DYS458 | DYS460 | DYS481 | | | | |
| | DYS518 | DYS533 | DYS549 | DYS570 | DYS576 | DYS627 | DYS635 | DYS643 | YGATAH4 | | | | |
| 2 | 36,38 | 15 | 11,14 | 13 | 29 | 24 | 10 | 11 | 13 | | | | |
| | 14 | 11 | 12 | 20 | 32 | 17 | 16 | 11 | 26 | | | | |
| | 43 | 12 | 12 | 18 | 17 | 16 | 23 | 10 | 12 | | | | |
| 3-Semen | 37,39 | 16 | 14,15 | 13 | 31 | 24 | 11 | 11 | 13 | | | | |
| | 15 | 10 | 12 | 21 | 32 | 15 | 17 | 10 | 30 | | | | |
| | 40 | 12 | * | 18 | 18 | 20 | 23 | * | 11 | | | | |
| 4 | 36,38 | 15 | 11,14 | 13 | 29 | 24 | 10 | 11 | 13 | | | | |
| | 14 | 11 | 12 | 20 | 32 | 17 | 16 | 11 | 26 | | | | |
| | 43 | 12 | 12 | 18 | 17 | 16 | 23 | 10 | 12 | | | | |

^{*} = Results were not received by a minimum of 10 participants for the loci indicated.

NM = Non-Male profile, YSTR results not expected.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.